Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 149

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 149
---
early development, will take time to develop and commercialize, if DiamiR is able to commercialize them at all. Prior to commercializing
any new products, DiamiR will need to conduct substantial research and development, including validation studies. DiamiR’s product
development efforts involve a high degree of risk and may fail for many reasons, including failure to demonstrate the clinical utility
of the product. As DiamiR develops products, DiamiR will have to make significant investments in product development and marketing resources.
In addition, competitors may develop and commercialize competing products faster than DiamiR is able to do so. If DiamiR is unable to
commercialize CogniMIR, DiamiR may not be able to carry out its business.

<div align='center'>78</div>

DiamiR relies on a sole supplier for some of the materials used in its tests and services, and DiamiR may not be able to find replacements or transition to alternative suppliers in a timely manner.

DiamiR relies on different sole suppliers for certain materials, kits
and supplies that DiamiR uses to perform its tests and services for its diagnostic tests. For example, DiamiR relies on Qiagen Gmbh for
its qPCR reagents and plates. DiamiR does not maintain an agreement with Qiagen Gmbh; their reagents are readily available for purchase,
additionally, the volume of DiamiR’s business is not material to them. In addition to Qiagen, DiamiR works with other multinational
stable corporations for its supplies. Although DiamiR does not currently have any agreements with other suppliers and technologies, DiamiR
believes other providers, such as ThermoFisher, which offers the TaqMan qPCR kits are easily accessible and DiamiR can quickly begin working
with them, if necessary. At the time of this filing all other reagents DiamiR uses are commonly available through multiple vendors on
similar terms.

From time to time, DiamiR also may purchase other reagents used in
its tests and services from sole-source suppliers. While DiamiR may develop alternate sourcing strategies for these materials and vendors,
DiamiR cannot be certain whether these strategies will be effective, or the alternative sources will be available in a timely manner.
If these suppliers can no longer provide DiamiR with the supplies DiamiR needs to perform its tests and services, if the materials do
not meet DiamiR’s quality specifications, or